Compare Equitable Holdings Inc. Common Stock (EQH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs IDEXX Laboratories, Inc. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.42B), while IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.9× Equitable Holdings Inc. Common Stock's market cap, and Equitable Holdings Inc. Common Stock pays a 2.16% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and IDEXX Laboratories, Inc. for 47 Days on average.
| EQH | IDXX | |
|---|---|---|
Market Cap | $14.42B | $41.68B |
Volume | 2,107,298 | 824,427 |
Sector | Financials | Health |
52-Week High | $54.50 | $766.68 |
52-Week Low | $35.34 | $504.70 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $5.48B | $42.58B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.
Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
